ZYBERNO
Stock Report
Updated Sep 1, 2026

SCYNEXIS, Inc. (SCYX)

Healthcare • NASDAQ

$5.23

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
SCYNEXIS, Inc. (SCYX) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-46.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (-212.3%)
Return on Capital (Capital Efficiency):CRITICAL (-790.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

SCYNEXIS, Inc. (SCYX) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.23
Market Cap:$61.84M

Valuation Multiples (4)

P/B Ratio:0.92x
P/S Ratio:3.22x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$7.32M

Price Action & Momentum (3)

Momentum Percentile:19 / 100
% of 52-Week High:49.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-34.3%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-212.3%
Net Margin Ttm:-117.2%
Ebitda Margin:-212.3%

TTM Performance (2)

Operating Margin Ttm:-212.3%
Net Margin Ttm:-117.2%

Yield Metrics (2)

Earnings Yield:$0.75
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:580.0%
Latest Earnings Filed:2026-08-10

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-8.9%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-46.8%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):-38.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.65x
Quick Ratio:9.65x
Cash Ratio:12.21x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:50,411,000.00
Cash And Cash Equivalents:71,100,000.00
Long Term Debt:$1.42M
Net Debt:-$69.16M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $19.22M
Linear Growth: -8.9%
📊 Click to view full SCYX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$40.79M

Bottom Line Performance (3)

Net income TTM: -$22.51M
Linear Growth: -46.8%
📊 Click to view full SCYX Net Income analysis & methodology →
Income Before Tax:-$20.89M
Ebitda Ttm:-40,788,000.00

Operating Expenses (5)

Operating Expenses:41,832,000.00
R And D Expense:26,240,000.00
Sga Expense:15,592,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:11,166.0%
Sga To Revenue Percentage:6,634.9%
Ebitda Margin:-212.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$74.97M
Current Assets:$56.24M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:8,040,000.00
Current Liabilities:5,825,000.00
Long Term Debt:$1.42M
Short Term Debt:$526.00K

Equity & Capital (3)

Equity:$66.93M
Retained Earnings:-$399.05M
Common Stock:60,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,265,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:568,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$5.92M
Linear Growth: -38.7%
$0.00

Investment Activities (1)

Investing Cash Flow:-$525.00K

Financing Activities (3)

Financing Cash Flow:$24.04M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.04
Eps diluted TTM: $0.04
Linear Growth: -11.0%
📊 Click to view full SCYX EPS analysis & methodology →
Earnings Per Share Ttm:-$1.90

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.63
Operating Cash Flow Per Share:-$0.45

Book Value & Capital (2)

Book Value Per Share:$5.66
Cash Per Share:6.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.29x
Working Capital Turnover Ttm:0.38x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:62.02
Cash Conversion Cycle:-2,060.02
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-8.9%
Net Income Growth Rate (Linear):-46.8%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):-38.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):4.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:SCYX
Company Name:SCYNEXIS, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:11.82M
Shares Outstanding Basic:11.82M
Shares Outstanding Diluted:11.82M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:30:05 UTC
Data Timestamp:2026-08-20T13:33:38.784498
Scroll to Top